• 17 September 2015
    The Cost of Meningitis

    Did you know that, globally, every year more than 1.7 million people contract meningitis? Bacterial meningitis and septicaemia are the most severe forms of the disease…and we mean severe.

    Read More
  • 09 September 2015
    The Meningococcal B Vaccine Debate

    The new meningococcal B vaccine has been licensed in many jurisdictions in the past 2 years. Since 2014, national health authorities have implemented regionally focused campaigns to respond to either outbreaks of Men B invasive disease (e.g. In 2 American Universities) or durable high incidence of Men B disease in some counties (e.g. Quebec hyper-endemic regions). As of September 2015, more than 100,000 doses of the Men B vaccine have been administered - surveillance has confirmed the safety profile and vaccine acceptance in targeted populations has been high. The control of the outbreaks, with large reductions in the incidence of Men B disease, suggests the vaccine is effective against Men B. It is too early to know the duration of protection afforded for those vaccinated.

    Read More
  • 27 August 2015
    Why immunize in 2015?

    In the interest of promoting more robust discourse around the importance of regular vaccinations for serious but preventable contagious conditions, MHA@GW is hosting a guest post series in honor of National Immunization Awareness Month (NIAM). During the month of August, they’re featuring blogs from thought leaders and advocates who were asked to answer the question, “Why immunize in 2015?”

    Read More